KTTA · Pasithea Therapeutics Corp
United States · RS rating 55 · As of 2026-11-03
| Price | 0.53 USD |
|---|---|
| 1-day change | +44.0% |
| RS rating (overall / 1M / 3M / 12M) | 55 / 91 / 88 / 28 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 30 / 17 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -33.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +64.0% |
| Market cap (USD) | $17.2M |